Legend Biotech Corporation Sponsored ADR LEGN
19.11
0.05
0.26%
as of 25 Sep
- Market cap
- $3.7B
- P/E
- 0.0×
Follow LEGN
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(22.54%) | (29.06%) | (25.19%) | (8.08%) | |
| (13.91%) | (17.44%) | (15.57%) | (5.32%) | ||
ROIC |
(46.34%) | (50.54%) | (39.15%) | (9.54%) | |
Return on Tangible Assets |
(26.07%) | (40.83%) | (35.99%) | (9.63%) | |
Average Days of Receivables |
0.50 | 4.65 | 0.54 | 0.00 | |
Free Cash Flow per Share |
(1.02) | (0.70) | (0.63) | (0.65) | |
Free Cash Flow |
(188.64) | (128.80) | (115.80) | (121.80) | |
Capital Expenditures |
(18.60) | (28.60) | (34.10) | (32.40) | |
Piotroski F-Score |
4.00 | 3.00 | 3.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(7.33%) | (4.41%) | (3.95%) | (3.80%) | |
Accounts Receivable Turnover |
936.64 | 105.53 | 1,101.02 | 0.00 | |
Accounts Payable Turnover |
5.54 | 6.71 | 7.74 | 7.23 | |
Inventory Turnover |
13.60 | 14.60 | 15.07 | 14.32 | |
Average Days of Payables |
104.30 | 74.23 | 52.90 | 51.10 | |
Days of Inventory on Hand |
29.71 | 28.62 | 26.41 | 27.44 | |
Tax Rate |
0.08 | 0.05 | 0.06 | 0.63 | |
Research and Development Expense of Revenue |
45.95% | 40.31% | 34.99% | 31.16% | |
Selling, General and Administrative Expense of Revenue |
35.61% | 33.20% | 31.54% | 29.49% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.71 | 0.34 | 0.33 | 0.98 | |
Depreciation/Fixed assets |
0.21 | 0.25 | 0.32 | 0.36 | |
Capex/Depreciation |
(0.80) | (0.99) | (0.87) | (0.72) | |
Revenue per Share |
4.92 | 5.58 | 6.15 | 6.80 | |
Operating CF per Share |
(0.92) | (0.54) | (0.44) | (0.48) | |
Capex per Share |
(0.10) | (0.16) | (0.18) | (0.17) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
(26.38%) | (28.85%) | (21.96%) | (7.20%) |
Columns are period end dates